Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice
Endocrinology · 2024
DOI: 10.1210/endocr/bqae038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Julia N Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85724, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Signal Transduction, Breast Neoplasms, Estrogens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Breast cancer bone metastases (BMET) are incurable, primarily osteolytic, and occur most commonly in estrogen receptor-α positive (ER+) breast cancer. ER+ human breast cancer BMET modeling in mice has demonstrated an estrogen (E2)-dependent increase in tumor-associated osteolysis and bone-resorbing osteoclasts, independent of estrogenic effects on tumor proliferation or bone turnover, suggesting a possible mechanistic link between tumoral ERα-driven osteolysis and ER+ bone progression. To explore this question, inducible secretion of the osteolytic factor, parathyroid hormone–related protein (PTHrP), was utilized as an in vitro screening bioassay to query the osteolytic potential of estrogen receptor- and signaling pathway–specific ligands in BMET-forming ER+ human breast cancer cells expressing ERα, ERß, and G protein–coupled ER. After identifying genomic ERα signaling, also responsibility for estrogen's proliferative effects, as necessary and sufficient for osteolytic PTHrP secretion, in vivo effects of a genomic-only ER agonist, estetrol (E4), on osteolytic ER+ BMET progression were examined. Surprisingly, while pharmacologic effects of E4 on estrogen-dependent tissues, including bone, were evident, E4 did not support osteolytic BMET progression (vs robust E2 effects), suggesting an important role for nongenomic ER signaling in ER+ metastatic progression at this site. Because bone effects of E4 did not completely recapitulate those of E2, the relative importance of nongenomic ER signaling in tumor vs bone cannot be ascertained here. Nonetheless, these intriguing findings suggest that targeted manipulation of estrogen signaling to mitigate ER+ metastatic progression in bone may require a nuanced approach, considering genomic and nongenomic effects of ER signaling on both sides of the tumor/bone interface.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85724, USA.
- Department of Medicine, University of Arizona, Tucson, AZ 86724, USA.
- Department of Surgery & Cancer, Imperial College London, London W12 0NN, UK.
ORCID-Profile: Simak Ali, Janet L Funk
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
- METAvivor
- Phoenix Chapter of ARCS Foundation
- Louise Foucar Marshall Foundation Dissertation Fellowship
Zitieren
APA
Cheng, J. N., Frye, J. B., Whitman, S. A., Ehsani, S., Ali, S., & Funk, J. L. (2024). Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice. Endocrinology. https://doi.org/10.1210/endocr/bqae038
Vancouver
Cheng JN, Frye JB, Whitman SA, Ehsani S, Ali S, Funk JL. Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice. Endocrinology. 2024. doi:10.1210/endocr/bqae038
BibTeX
@article{Cheng2024,
author = {Cheng, Julia N and Frye, Jennifer B and Whitman, Susan A and Ehsani, Sima and Ali, Simak and Funk, Janet L},
title = {Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice},
journal = {Endocrinology},
year = {2024},
doi = {10.1210/endocr/bqae038}
}
EUVIMED